Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

July 31, 2024

https://www.globenewswire.com/news-release/2024/07/30/2920900/29248/en/Anavex-Life-Sciences-Announces-Translational-Biomarker-Data-for-ANAVEX-2-73-blarcamesine-in-Fragile-X-Syndrome-Major-Cause-of-Autism-at-the-19th-NFXF-International-Fragile-X-Confer.html

ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS)

Therapeutic potential to address behavioral and cognitive deficits in individuals with neurodevelopmental disorders

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.